SCHEMBL20057549

SCHEMBL20057549

CNC(=O)Nc1ccc(N/C(=N\C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
CYP17A1 P05093 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
KMT2A Q03164 1/20 0.38
MAPK14 Q16539 1/20 0.38
PSMB8 P28062 1/20 0.38
POLB P06746 1/20 0.36
PTPN11 Q06124 1/20 0.36
MAPKAPK2 P49137 2/20 0.35
NAMPT P43490 1/20 0.35
MAP4K4 O95819 1/20 0.35
CTSK P43235 1/20 0.34
EPHX2 P34913 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20323597 0.90 NR1H4 (0.39) ALDH1A1CYP17A1NR1H4KMT2APOLB
SCHEMBL13293398 0.89 CYP17A1 (0.43) ALDH1A1CYP17A1NR1H4MAPK14PSMB8
SCHEMBL14155353 0.89 CYP17A1 (0.48) CYP17A1NR1H4PSMB8PTPN11MAPKAPK2
SCHEMBL10092627 0.89 CYP17A1 (0.48) CYP17A1NR1H4PSMB8PTPN11MAPKAPK2
SCHEMBL3777963 0.86 CYP17A1 (0.40) ALDH1A1CYP17A1NR1H4KMT2AMAPK14
SCHEMBL17894453 0.86 MIF (0.45) ALDH1A1CYP17A1NR1H4KMT2AMAPK14
SCHEMBL17902832 0.86 MIF (0.45) ALDH1A1CYP17A1NR1H4KMT2AMAPK14
SCHEMBL3777965 0.86 CYP17A1 (0.40) ALDH1A1CYP17A1NR1H4KMT2AMAPK14
SCHEMBL13062960 0.86 CYP17A1 (0.40) ALDH1A1CYP17A1NR1H4KMT2AMAPK14
SCHEMBL18256797 0.86 MIF (0.45) ALDH1A1CYP17A1NR1H4KMT2AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885CYP17A1 911/4885NR1H4 131/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885CYP17A1 911/4885NR1H4 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.